Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Amgen, Inc. (AMGN) Price & Performance

Goldman Sachs Physical Gold ETF
Amgen, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

Goldman Sachs Physical Gold ETF vs Amgen, Inc. — how do they compare? Goldman Sachs Physical Gold ETF trades at $40, while Amgen, Inc. trades at $368.19 (market cap $198.67B). The key difference: Amgen, Inc. pays a 2.74% dividend while Goldman Sachs Physical Gold ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.

AAAUAMGN
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$388.16
52-Week Low
$32.29$271.18
Market Cap
$198.67B
Enterprise Value
$243.95B
Dividend Yield
2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.

Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.

Amgen, Inc.

Amgen (AMGN) trades at $368.10, down 1.62% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net income margin of 20.96% and has beaten earnings estimates for three consecutive quarters. Recent news includes a favorable court ruling blocking a price cap on Enbrel and analyst upgrades, though regulatory challenges for Tavneos in Europe pose headwinds. Cash flow from operations remains robust at nearly $10 billion annually.

The outlook for AMGN is positive with steady revenue growth and high margins, but investors face risks from patent expirations and regulatory scrutiny. Analyst consensus is bullish with a $358.25 price target, though the current price exceeds this, suggesting near-term consolidation may occur. The company's strong cash generation supports dividend payments, but high debt levels require monitoring.

Returns comparison

Trailing returns across standard periods

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN